Interview: Amal Al-Saeed @amal222424, Photo: Abdulaziz Al-Youssef
Fox Space source of local, national and world news
Interview: Amal Al-Saeed @amal222424, Photo: Abdulaziz Al-Youssef
Clinical trials highlight secondary therapeutic benefits of GLP-1 receptor agonists, expanding total addressable markets for pharmaceutical developers.
Biopharmaceutical firms are leveraging automated synthesis platforms to target previously undruggable intracellular pathway proteins.
Phase III data shows significant reductions in liver fat accumulation with minimal side effects.
Soaring demand for anti-obesity medications prompts self-insured employers to implement strict coverage criteria to manage costs.
High demand for metabolic therapeutics drives unprecedented capital expenditure in sterile injectable drug manufacturing.
Widespread adoption of metabolic therapeutics reshapes consumer demand patterns and healthcare expenditure.